The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-20. Anything still debated is marked as such rather than presented as settled.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
==== Self-cleaning coatings ==== Photocatalytic coatings include components (additives) that catalyze reactions, generally through a free radical mechanism, when excited by light. The photocatalytic activity (PCA) of a material provides a measure of its reactive potential, based on the ability of the material to create an electron hole pair when exposed to ultraviolet light. Free radicals formed can oxidize and break down organic materials, such as latex binders found in waterborne coatings. Antimicrobial coatings systems take advantage of this by including photocatalytically active compounds in their formulations (i.e. titanium dioxide) that cause the coating to "flake" off over time. These flakes carry the microbes along with them, leaving a "clean" coating behind. Systems like this are often described to be self-cleaning.
Dynamic and interactive HTML5 charting Improved and revamped scheduler (additional features over what is added in CF10 Standard) Object relational mapping enhancements The lists above were obtained from the Adobe web site pages describing "new features", as listed first in the links in the following list. CF10 was originally referred to by the codename Zeus, after first being confirmed as coming by Adobe at Adobe MAX 2010, and during much of its prerelease period. It was also commonly referred to as "ColdFusion next" and "ColdFusion X" in blogs, on Twitter, etc., before Adobe finally confirmed it would be "ColdFusion 10". For much of 2010, ColdFusion Product Manager Adam Lehman toured the US setting up countless meetings with customers, developers, and user groups to formulate a master blueprint for the next feature set. In September 2010, he presented the plans to Adobe where they were given full support and approval by upper management. The first public beta of ColdFusion 10 was released via Adobe Labs on 17 February 2012.
On November 3, 2017, 31-year-old Geoffrey Howe, the prison's maintenance mechanic, died at Sentara Norfolk General Hospital, and was thus the fourth and final victim to die in this case. Autopsy reports revealed that all the four deceased victims suffered from multiple stab wounds and blunt force injuries. Smith was reportedly stabbed 67 times (including 45 stab wounds to his body) and sustained a total of 32 blunt force injuries to his head and neck. Shannon died from an anoxic brain injury caused by the blunt force trauma to her head. Howe himself died due to extensive brain and skull injuries, and also lost his left eye due to the brutality of the attack. Darden, who died due to a fatal slicing wound on her neck, also had 13 blunt force injuries to her head.
=== Functions of macrophytes in aquatic systems === Macrophytes perform many ecosystem functions in aquatic ecosystems and provide services to human society. One of the important functions performed by macrophyte is uptake of dissolved nutrients including nitrogen and phosphorus. Macrophytes are widely used in constructed wetlands around the world to remove excess N and P from polluted water. Besides direct nutrient uptake, macrophytes indirectly influence nutrient cycling; especially N cycling through influencing the denitrifying bacterial functional groups that are inhabiting on roots and shoots of macrophytes. Macrophytes promote the sedimentation of suspended solids by reducing the current velocities, impede erosion by stabilising soil surfaces. Macrophytes also provide spatial heterogeneity in otherwise unstructured water column. Habitat complexity provided by macrophytes tends to increase diversity and density of both fish and invertebrates. The additional site-specific macrophytes' value provides wildlife habitat and makes treatment systems of wastewater aesthetically satisfactory.
candidate gene A gene whose location on a chromosome is associated with a particular phenotype (often a disease-related phenotype), and which is therefore suspected of causing or contributing to the phenotype. Candidate genes are often selected for study based on a priori knowledge or speculation about their functional relevance to the trait or disease being researched.
Sources: en.wikipedia.org
When one molecule of a base via complete ionization produces one hydroxide ion, the base is said to be a monoacidic or monoprotic base. Examples of monoacidic bases are: Sodium hydroxide, potassium hydroxide, silver hydroxide, ammonium hydroxide, etc.
==== Tryptamine and lysergamide psychedelics ==== Austrian anthropologist and ethnobotanist Blas Pablo Reko, traveling through Central and South America, wrote of the use of teonanacatl by native Mexican people in Oaxaca in 1919. Reko subsequently sent samples of teonanacatl (Psilocybe mexicana) as well as Ipomoea violacea (morning glory) seeds to Swedish anthropologist Henry Wassén in 1937. Reko had obtained the mushroom sample from Austrian engineer Robert Weitlaner who was working in Mexico. Eventually, Wassén forwarded Reko and Weitlaner's mushroom sample to Harvard University, where the mushrooms came to the attention of American ethnobotanist Richard Evans Schultes. However, they had decomposed so badly that they could not be identified. Prior to Wassén obtaining specimens around 1936, the existence of teonanacatl was very controversial and was debated and even denied by some. In 1938, a small group of Westerners, which included Weitlaner's daughter and American anthropologist Jean Basset Johnson, attended a mushroom ceremony. They were the first Westerners known to do so and described the event. Schultes published reviews of teonanacatl being a hallucinogenic mushroom in the late 1930s. Schultes obtained specimens of three of the hallucinogenic mushrooms used in ceremonies, including Psilocybe caerulescens, Panaeolus campanulatus, and Stropharia cubensis, but further investigations of the mushrooms were interrupted by World War II.
Juxtacrine signaling is a type of intercellular communication that is transmitted via oligosaccharide, lipid, or protein components of a cell membrane, and may affect either the emitting cell or the immediately adjacent cells. It occurs between adjacent cells that possess broad patches of closely opposed plasma membrane linked by transmembrane channels known as connexons. The gap between the cells can usually be between only 2 and 4 nm.
The PRI ruled Mexico for over 70 years, during which cartels grew in power and anti-drug efforts targeted the seizure of marijuana and opium crops in remote regions. In 2000, Vicente Fox of the National Action Party (PAN) became the first non-PRI president since 1929; his term saw declining homicide rates through 2007, and initially, broad public optimism about regime change. Los Zetas, then the armed wing of the Gulf Cartel, based in Nuevo Laredo, Tamaulipas, escalated violence to unprecedented levels in the summer of 2003 through gruesome violence and military-like tactics against the Sinaloa Cartel. Los Zetas turf conflict also instilled terror against journalists and civilians of Nuevo Laredo. This set a new precedent, which cartels later mimicked. These activities were not widely reported by the Mexican media at the time. However, key conflicts occurred, including the Sinaloa Cartel counterattacks and the advance on the Gulf Cartel's main regions in Tamaulipas. It is estimated that in the first eight months of 2005, about 110 people died in Nuevo Laredo, Tamaulipas, as a result of the fighting between the Gulf and Sinaloa cartels. The same year, there was another surge in violence in the state of Michoacán as La Familia Michoacana drug cartel established itself after splintering from its former allies, the Gulf Cartel and Los Zetas.
=== Return to Greece === After his Berlin, Dresden and New York years, Zervas decided to return to Greece in 1937. He was immediately appointed full Professor of Organic Chemistry and Biochemistry at the Aristotle University of Thessaloniki in recognition of his distinguished international work. He stayed in this position until 1939, when he was invited to the Professorship of Organic Chemistry at the University of Athens and also appointed director of the Laboratory of Organic Chemistry of the same institution. He continued conducting research, despite the severe limitations he often faced from the lack of equipment and funding. Concurrent to research, Zervas taught organic chemistry, oversaw the laboratory and guided many generations of young chemists as doctoral advisor for the 29 years he held the post at the University of Athens. During the Axis occupation of Greece Zervas played an active part in the Greek Resistance as a member of EDES; he was imprisoned twice, first by the Italian and then by the German occupying forces, and his laboratory was destroyed. Following the liberation of Greece, Zervas managed to secure a small part of the American postwar aid for repairs in the University of Athens and the Athens Polytechnic, and thus rebuilt his laboratory in 1948–1951. In the following years, guided by a sense of personal and professional duty, Zervas voluntarily took on a variety of responsibilities within the Greek state. At his own insistence, he never got paid for these posts and kept receiving only his professorial salary.
Sources: en.wikipedia.org
== History == Phencyclidine was initially discovered in 1926 by Arthur Kötz and his student Paul Merkel as a product of a Grignard reaction of 1-piperidinocyclohexancarbonitrile. It was again synthesized in 1956 by chemist H Victor Maddox and brought to market as an anesthetic medication by pharmaceutical company Parke-Davis, now a subsidiary of Pfizer. Its use in humans was disallowed in the US in 1965 due to the high rates of side effects, while its use in animals was disallowed in 1978. Moreover, ketamine was discovered and was better tolerated as an anesthetic. PCP is classified as a schedule II drug in the US. Derivatives of PCP have been sold for recreational and non-medical use.
== History == Two main studies showed that treosulfan is at least as effective as busulfan, another medicine used to prepare people for haematopoietic stem cell transplantation. In one of the studies, involving 570 adults with acute myeloid leukaemia (a blood cancer) or myelodysplastic syndromes (conditions in which large numbers of abnormal blood cells are produced), 64% of patients given treosulfan (with fludarabine) had a successful transplant and were alive and disease-free after 2 years, compared with 51% of patients given busulfan (with fludarabine). In an additional study in 70 children with blood cancers, 99% of children given treosulfan (with fludarabine) were alive three months after their transplant. Efficacy was evaluated in MC-FludT.14/L Trial II (NCT00822393), a randomized active-controlled trial comparing treosulfan to busulfan with fludarabine as a preparative regimen for allogeneic transplantation. Eligible patients included adults 18 to 70 years old with AML or MDS, Karnofsky performance status ≥ 60%, and age ≥ 50 years or hematopoietic cell transplantation comorbidity index [HCTCI] score > 2. There were 570 patients randomized to treosulfan (n=280) or busulfan (n=290).
These processes are increasingly aligned although important differences remain and drug developers must prepare separate documents. New development pathways have been developed to help with the approval of new antimicrobial agents that address unmet needs such as the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD). These new pathways are required because of difficulties in conducting large definitive phase III clinical trials in a timely way. Some of the economic impediments to the development of new antimicrobial agents have been addressed by reimbursement schemes that delink payment of antimicrobials from volume-based sales. In the UK, a market entry reward scheme has been pioneered by the National Institute for Clinical Excellence (NICE) whereby an annual subscription fee is paid for use of strategically valuable antimicrobial agents – cefiderocol and ceftazidime-aviabactam are the first agents to be used in this manner and the scheme is potential blueprint for comparable programs in other countries. The available classes of antifungal drugs are still limited but as of 2021 novel classes of antifungals are being developed and are undergoing various stages of clinical trials to assess performance. Scientists have started using advanced computational approaches with supercomputers for the development of new antibiotic derivatives to deal with antimicrobial resistance.
The results of studies which have looked at healing of electrosurgical wounds compared to scalpel wounds vary widely but it has been found that electrosurgerical equipment minimises bleeding and most patients experience very little post-operative pain after the procedure. There may be more damage to adjacent tissues, slower wound healing and more inflammatory response than the scalpel technique.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.